© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Interstitial lung disease
FDA Approves Nerandomilast, First New IPF Treatment in More Than a Decade
October 08, 2025
Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.
The IPF Pipeline is Set to Deliver: The 3 Top Contenders
September 10, 2025
Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.
Nerandomilast Meets Primary Endpoint in Phase III FIBRONEER-ILD Trial in Progressive Pulmonary Fibrosis
February 11, 2025
Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.